A phase II trial of TPI 287 in patients with metastatic prostate cancer who have progressive neoplastic disease following treatment with one prior taxane regimen.

Trial Profile

A phase II trial of TPI 287 in patients with metastatic prostate cancer who have progressive neoplastic disease following treatment with one prior taxane regimen.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2014

At a glance

  • Drugs TPI 287 (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Cortice Biosciences
  • Most Recent Events

    • 24 Jan 2012 Actual end date (1 Aug 2008) added as reported by ClinicalTrials.gov.
    • 24 Jan 2012 Planned end date changed from 1 Dec 2008 to 1 Aug 2008 as reported by ClinicalTrials.gov.
    • 24 Jan 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top